Epeleuton is under clinical development by Afimmune Biopharma and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Epeleuton’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epeleuton overview

Epeleuton (AF-102) is under development for the treatment of non alcoholic fatty liver disease (NAFLD), idiopathic pulmonary fibrosis, alcoholic hepatitis, non-alcoholic steatohepatitis (NASH), type-2 diabetes, metabolic syndrome, rare blood disorders, sickle cell disease, cardiovascular risk reduction, hypertriglyceridemia, chronic obstructive pulmonary disease (COPD), Coronavirus disease 2019 (COVID-19) and atherosclerosis. It is a bioactive lipid administered orally as a capsule. It was under development for  idiopathic pulmonary fibrosis in EU.

Afimmune Biopharma overview

AFIMMUNE Biopharma is a drug discovery and development company working on inflammatory conditions of the primary organs including the heart and the liver. AFIMMUNE Biopharma is headquartered in Leopardstown, Dublin, Ireland.

For a complete picture of Epeleuton’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.